Novavax Inc. (NVAX) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Novavax’s revenue went from $15M in fiscal 2016 to $1.1B in fiscal 2025, growth of about 61.1% a year.
Net income in fiscal 2025 was $440M, a net margin of 39.2%; the highest of the period.
Over the twelve months to September 30, 2026, revenue was $412M and net income -$77M.
Free cash flow was -$250M in fiscal 2025 and positive in 1 of the 10 years shown.
The diluted share count rose 1178% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $412M | $1.1B | $682M | $984M | $2.0B | $1.1B | $476M | $19M | $34M | $31M | $15M |
| Gross profit | $321M | $1.1B | $479M | $640M | $1.1B | $1.1B | $476M | — | — | — | — |
| Operating income | -$87M | $453M | -$249M | -$567M | -$645M | -$1.7B | -$417M | -$121M | -$174M | -$172M | -$269M |
| Net income | -$77M | $440M | -$187M | -$545M | -$658M | -$1.7B | -$418M | -$133M | -$185M | -$184M | -$280M |
| EPS (diluted) | $-0.52 | $2.58 | $-1.23 | $-5.41 | $-8.42 | $-23.44 | $-7.27 | $-5.51 | $-9.99 | $-12.56 | $-20.60 |
| R&D | $294M | $342M | $391M | $738M | $1.2B | $2.5B | $747M | $114M | $174M | $168M | $238M |
| Revenue growth | — | +64.7% | −30.6% | −50.4% | +72.9% | +141.0% | +2448.5% | −45.6% | +10.0% | +103.1% | −57.6% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$239M | -$245M | -$87M | -$714M | -$416M | $323M | -$43M | -$137M | -$185M | -$144M | -$259M |
| Capital spending | -$4M | -$6M | -$13M | -$54M | -$89M | -$57M | -$55M | -$2M | -$1M | -$4M | -$18M |
| Free cash flow | -$243M | -$250M | -$100M | -$768M | -$505M | $265M | -$97M | -$138M | -$186M | -$149M | -$277M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based pay | $32M | $36M | $48M | $85M | $130M | $184M | $128M | $17M | $18M | $20M | $19M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $735M | $923M | $569M | $1.3B | $1.5B | $711M | $79M | $92M | $157M | $235M |
| Debt | — | $29M | $203M | $281M | $450M | $201M | $160M | $11M | — | — | $0 |
| Equity | — | -$128M | -$624M | -$717M | -$634M | -$352M | $627M | -$186M | -$168M | -$102M | -$6M |
| Total assets | — | $1.2B | $1.6B | $1.8B | $2.3B | $2.6B | $1.6B | $173M | $208M | $302M | $394M |
| Shares (diluted) | 165M | 173M | 152M | 101M | 78M | 74M | 58M | 24M | 18M | 15M | 14M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 78.0% | 93.5% | 70.3% | 65.0% | 54.5% | 100.0% | 100.0% | — | — | — | — |
| Operating margin | -21.2% | 40.3% | -36.5% | -57.6% | -32.5% | -147.1% | -87.6% | -646.1% | -507.2% | -550.8% | -1752.8% |
| Net margin | -18.6% | 39.2% | -27.5% | -55.4% | -33.2% | -152.1% | -87.9% | -711.0% | -538.8% | -589.5% | -1823.5% |
| FCF margin | -59.1% | -22.3% | -14.7% | -78.0% | -25.5% | 23.2% | -20.4% | -742.0% | -543.0% | -476.9% | -1804.0% |
| ROIC | — | — | — | — | — | — | -52.9% | — | — | — | — |
| ROE | — | -344.6% | 30.1% | 76.0% | 103.8% | 495.8% | -66.7% | 71.3% | 110.0% | 180.6% | 5048.1% |
Frequently asked questions
What is Novavax’s annual revenue?
$1.1B in fiscal 2025 and $412M over the twelve months to September 30, 2026.
How much profit does Novavax make?
Net income was $440M in fiscal 2025 (net margin 39.2%).
Is Novavax’s revenue growing?
Yes: revenue rose 64.7% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.